FV Leiden Mutation and Deep Venous Thrombosis in Vojvodina: A Case-Control Study
Between September 2007 and February 2010, the occurrence of symptomatic deep venous thrombosis (DVT) was investigated in a cohort of 79 consecutive patients. A case-control study inclu ded 71 healthy controls matched with cases for sex and age. The prevalence of factor V G1691A mutation genotype was analyzed. Eighteen cases (22.79%; 95% confidence interval (CI) 13.53% to 32.03%) and four controls (5.63%; 95% CI 0.27% to 10.99%) were heterozygous carriers of FV Leiden (p= 0.025). The odds ratio for DVT was 4.94 (95% CI 1.58 to 15.42) and the relative risk 4.04 (95% CI 1.44-11.38) compared with FV 1691G carriers. Four cases were homozygous carriers of FV Leiden, giving a prevalence of 5.06% (95% CI 0.23 to 9.89%) and no controls, therefore OR and RR calculation was based on the prevalence of homozygotes in the general Caucasian population. The OR for DVT was 47.28 (95% CI 0.04 - 52167.3) and the RR 45.57 (95% CI 0.04 to 49540.77; p=0.025) compared with FV 1691 G carriers. Our study confirms that factor V Leiden carriers in Vojvodina, as in similar studies previously carried out in other populations, have an increased risk of developing DVT. The evaluated risk of DVT in heterozygous carriers of the mutation is four- to five-fold higher, whereas for homozygous carriers it is 45- to 48-fold higher than in non-carriers. These results confirm that patients with DVT and their relatives should undergo screening for FV Leiden mutation.
If the inline PDF is not rendering correctly, you can download the PDF file here.
Milić D. Disorders of the coagulation system in the patients with deep vein thrombosis of lower extremities. Acta biologica iugoslavica 2000; 1: 43-56.
Lane DA Mannucci PM Bauer KA Bertina RM Bochkov NP Boulyjenkov V Chandy M et al. Inherited Throm bophilia: Part I. Thrombosis and Haemostasis 1996; 76: 651-62.
Franco RF Reitsma PH. Genetic risk factors of venous thrombosis. Human Genetics 2001; 109: 369-84.
Rizk N Toon PG Watson D Jones V. Protein S deficiency and factor V Leiden gene in pregnancy. Journal of Obstetrics and Gynaecology 1998; 2: 178-9.
Mandalà M Curigliano G Bucciarelli P Ferretti G Mannucci PM Colleoni M et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Annals of Oncology 2004; 15 (4): 590-3.
Bertina RM Koeleman BPC Koster T Rosendaal FR Dirven RJ De Ronde H Van der Velden PA Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
Mitić G. Nasledna trombofilija i trombozne komplikacije u trudnoći [disertacija]. [Novi Sad]: Univerzitet u Novom Sadu; 2008; 147.
Angelopoulou K Nicolaides A Constantinou DC. Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population. Clin Appl Thromb Hemost 2000; 6 (2): 104-7.
Franco RF. Heterogeneous ethnic distribution of the factor v leiden mutation. Genet Mol Biol 1999; 22 (2): 143-5.
Seligsohn U Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31.
Leonard DGB Bagg A. Molecular pathology in clinical practice. Springer 2006: 145-6pp. [Internet]. [Cited June 2010] Available at http://www.springerlink.com/content/w67t13/
Mei JV Alexander RJ Adam BW Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. Journal of Nutrition 2001; 131: (163): 1-6.
Kovač M Miković D Antonijević N Rakičević Lj Đorđević V Radojković D Elezović I. FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population. J Thromb Thrombolysis 2008; 25: 284-7.
Kearon C Crowther M Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 2000; 51: 169-85.
Hirsh J Kearon C Ginsberg J. Duration of anticoagulation therapy after first episode of venous thrombosis in patients with inherited thrombophilia. Arch Intern Med 1997; 157: 2174-7.